The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
From the BBC website regarding “British man tests first personalised melanoma vaccine”
3W - .bbc.co.uk/news/health-68897731
Speaking to BBC Radio 4 Today Programme, he said: "[The trial] gave me a chance to feel like I was actually doing something to fight a potential unseen enemy.
"Scans showed I was radiologically clear, obviously there is still the chance I had cancer cells floating around undetected.”
Would not PARSORTIX have a role in this?
The assumption being that any government formed by the current opposition would permit the "Tax Avoidance" to continue.
Abolition of these HMRC concessions are an easy target to finance even more generous, and true socialist giveaways!
Hear, Hear!
But which party should you vote for in the forthcoming General Election to reverse this situation?
A dilemma?
POLhave a 20% plus holding in GCM plus other investments - but look what happened.
Is it still extant and tradeable?
It's an interesting investment story that should make investors in the AIM market very wary .
History to repeat itself?
Angle AGL today announced that it has developed sample-to-answer solutions for real-time NGS DNA analysis of both ctDNA (fragments of DNA released mainly by dying cells) and CTCs (living cancer cells) from a single tube of patient blood. Results announced today come from forty-seven patient samples in breast, lung, prostate and ovarian cancers analysed for both ctDNA and CTC-DNA using a pan-cancer panel run on an Illumina NGS system.
Interestingly they announced on Jan second that it has signed a contract with the global pharmaceutical company, Eisai Inc. ("Eisai"). Under the agreement, ANGLE will provide CTC analysis with its Portrait HER2 assay to assess breast cancer patients' HER2 (human epidermal growth factor receptor 2) status in a Phase II study of the HER2 targeting antibody-drug conjugate (ADC) BB-1701.
BB-1701 is an ADC that is composed of Eisai’s in-house developed anticancer agent eribulin, and anti-HER2 antibody using a linker, and is expected to have anti-tumor effects on breast, lung and other solid tumors that express HER2. The linker-payload, which uses eribulin as a payload, is a proprietary technology platform developed by Eisai's U.S. research base Exton Site, and Eisai is investigating the possibilities of using this platform to link to various antibodies. Under a license agreement signed by the two companies in 2018, Eisai has granted BlissBio global exclusive development rights for several ADCs to use eribulin as the payload. Based on the status of the Phase I/II clinical trials of BB-1701 currently being conducted by BlissBio, the both companies have decided to co-develop this drug.
How does this relate to AVCT’s activities. Are Eisai in the same competitive arena or is their approach quite different? Does AGL’s products have a place within the AVCT sphere? I am no expert but curious to know if there is a link in the fight against cancer
Proactive One2One Investor Fora
Next one is 11 January 2024 at the Chesterfield Mayfair Hotel, 35 Charles Street, Mayfair - 6:00pm
Join the audience of astute high net worth investors, fund managers, private client brokers and analysts
Look beyond the numbers and meet the people creating the value for shareholders
Each company, and on this occasion the list includes ANGLE plc, has a presentation slot followed by Q & A, giving you the chance to discover the real story
"academic and translational research customers"
Once again a very limited market.
Large scale commercialisation is key and Angle's BOD seems incapable of recognising or implementing this.
Are they fit for purpose?
It is HMG intention that all shareholdings should be digitised and share certificates would become history. Unfortunately, the Digitisation Taskforce has failed to take into account the ramifications of dispensing with share certificates, and the substitution of shareholdings through the mechanism of nominee accounts, or similar.
Legally, it is only entities appearing on a company’s share register that are members of a company, and consequently the legal owners thereof.
Investors using nominee accounts – everyone who has an ISA, SIPP and Trading account, will have their purchase and sales reflected in nominee accounts. As such, they have an economic interest in the invested company and are therefore the beneficial owners of the underlying shares. As beneficial owners, their rights in regard to control of the company is limited to those that the nominee may care to grant. Even these rights are restricted.
I doubt that the current Digitisation Taskforce will be successful in completing their task, as they have failed to indicate how they will address the disenfranchisement of current legal shareholders of shares, when digitisation transfers them to nominee accounts.
But of course, the Companies Act 2009 could be changed to remove the distinction between Legal and Beneficial owners of shares. We shall see!
It's not only EOG shareholders that have an issue with the Board of a company.
This extracted from another BB on LSE.
" While the Board is pleased that the majority of resolutions were carried with large majorities, it notes that resolution 3, to re-appoint "X" who is to retire by rotation under the Articles, received c.32% of votes against. The Board is committed to continuing our engagement with shareholders to understand the views of those who voted against resolution 3 and will consult with them over the next few months to listen carefully to feedback and determine any next steps. In accordance with the UK Corporate Governance Code, a further statement will be published detailing the outcome of the shareholder engagement, including any actions taken as a result, within six months and a final summary will be included in the Company's 2024 Annual Report.
Fantastic news. This chap has brought nothing to the table. and seems to have little interest in the company."
End of extract.
Compare this stament from a BoD who understand shareholders, and governance, with the EOG reaction to the resolution to confirm Stuart's appointment!
We need changes - and urgently.
The resolution to confirm the appointment of Alastair Stuart to the Board failed on the “show of hands” poll at the AGM. My recollection is that of the six shareholders who voted one, the Chairman, supported the appointment whilst the other five shareholders rejected the appointment. Consequently, the Chairman changed the nature of the resolution and the resolution was passed using the votes of those he now deems not to be the owners of the company.
They can’t have it both ways!!!